CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 50 enrolled
Drug / intervention
biphasic insulin aspart 30drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01487811
NCT01487811Phase 1Completed
CompareCT.gov

Bioequivalence of Two Biphasic Insulin Aspart 30 (NovoLog® Mix 70/30) Formulations (Current and New Formulation With Glycerol): A Randomized, Double-Blind, Two-Period Crossover Study in Healthy Volunteers

Novo Nordisk A/S·interventional·Posted Dec 7, 2011·Updated Jan 6, 2017

In Brief

A Phase 1 clinical trial evaluating biphasic insulin aspart 30 for Diabetes and Healthy. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This trial is conducted in the United states of America (USA). The aim of this trial is to compare two formulations of biphasic insulin aspart 30 in healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Healthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 7, 2011
Enrollment StartMay 1, 2005
Primary CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.6 years ago

Interventions

biphasic insulin aspart 30drug

Single dose administrated subcutaneously (s.c., under the skin)